Inovio Pharmaceuticals, Inc., announced on Wednesday that its vaccine, SynCon, against the Ebola virus will enter the first phase of clinical trials.
There are currently no known treatments or vaccines for Ebola, which has broken out in west Africa and killed more than 2,900 people. The virus' propensity to mutate into different strains complicates research into finding treatment and vaccination options.
The company observed that 100 percent of infected guinea pigs and mice survived in pre-clinical testing. Vaccinated animals also showed no signs of weight loss and researchers found increases in antibodies and T-cell induced by the vaccine.
The research suggests that SynCon could potentially prevent and treat Ebola cases. Inovio, in partnership with GeneOne, will take the vaccine to phase I of clinical trials in the first half of 2015.
The vaccine utilizes DNA-based immunotherapy to produce effective characteristics and is capable of empowering the immune system based on pre-clinical trials.
“We are therefore taking the steps with our collaborator to establish the safety and immunogenicity of our Ebola vaccine in humans and be in a position to further advance these agents to help fight this challenging disease," J. Joseph Kim, the president and CEO of Inovio, said.